Douglas Edward Williams
Independent Chairman of the BoardDr. Douglas Edward Williams, also known as Doug, Ph.D., is Independent Chairman of the Board of Climb Bio, Inc. from November 2024. He has been a Director of eGenesis, Inc. since August 2025. He is Independent Director at Camp4 Therapeutics Corporation from March 2025 and serves as its Chairman since September 09, 2025. He serves as an Independent Chairman since July 2025 at Draig Therapeutics Ltd. Dr. Williams has served as Chief Executive Officer of TriArm Therapeutics Ltd. He served as Executive Vice President and President of Research and Development at Sana Biotechnology, Inc. since April 13, 2023 until April 18, 2024. He serves as an Independent Director at Panacea Acquisition Corp. II since April 6, 2021. He served as a Director at Stablix, Inc., since January 2023 until 2026. He held several roles at Tecfidera and Spinraza. He was the Chief Executive Officer and President of Codiak Biosciences, Inc. since August 2015 and had been its Director since August 2015 until April 2023. He served as Director of CytoImmune Therapeutics, Inc until 2024. Dr. Williams has contributed to the development of several transformative drugs, including LEUKINE®, ENBREL®, ADCETRIS®, TECFIDERA®, APROLIX®, ELOCTATE® and SPINRAZA®. Dr. Williams is Chair of Strategic Advisory Board of Sporos Bioventures from January 2022. He was Independent Non-Executive Chairman at AC Immune SA since June 28, 2019 until June 19, 2025. Dr. Williams served as Scientific Advisor of Dewpoint Therapeutics, Inc. until 2022. He served as an Executive Vice President of Research & Development at Biogen Inc. from January 5, 2011 to July 10, 2015 and Biogen Idec Ltd. until August 6, 2015. From 2004 to 2010, Dr. Williams served in various roles at ZymoGenetics, Inc., a former publicly held pharmaceutical company and a subsidiary of Bristol-Myers Squibb Company, a publicly held pharmaceutical company. He was CEO and member of the board of directors at ZymoGenetics from January 2009 to October 2010. Dr. Williams joined ZymoGenetics, Inc. on September 7, 2004 as Chief Scientific Officer and served its Executive Vice President of Research and Development from September 7, 2004 to July 2, 2007; Chief Executive Officer from January 2, 2009 to November 2010 and President from July 2, 2007 to January 2009. He joined Codiak BioSciences in 2015, Dr. Williams was previously Biogen’s Executive Vice President, Research and Development, serving in this role from January 2011 to July 2015. He held leadership positions within the biotechnology industry, including Chief Scientific Officer and Executive Vice President of Research and Development at Seattle Genetics and Senior Vice President and Washington Site Leader at Amgen. He serves as Director at Ovid Pharmaceuticals. Dr. Williams served as a Secretary of Fred Hutchinson Cancer Research Center. Dr. Williams has scientific and senior leadership experience. He serves as Director at Cygnal Therapeutics and Xenikos. He had been Independent Non-Executive Director of AC Immune SA since April 27, 2018 until June 19, 2025. Dr. Williams has experience within the biotechnology industry and held senior level positions at a number of biotechnology companies. He served as the Chief Scientific Officer and Executive Vice President of Research and Development at Seattle Genetics, Inc., from July 17, 2003 to September 10, 2004. Dr. Williams served as Director/Head of Health and Strategic Development at Genesis Research & Development Corp. Ltd., from October 2002 to March 25, 2005. He served as the Senior Vice President and Washington Site Leader at Amgen Inc., from July 2002 to October 2002 and also as the Senior Vice President of Basic Research. He served as Head of Research and a Member of The Executive Team at Immunex Corp., where he played a significant role in the discovery and development of rheumatoid arthritis drug Enbrel. Dr. Williams served as an Executive Vice President and Chief Technology Officer at Immunex Corporation from October 1999 to July 2002 and served as its Vice President of Research and Development from 1992 to September 1994 and Senior Vice President of Discovery Research from October 1994 to October 1999. Dr. Williams was Director of Immunex. Dr. Williams joined Immunex Corporation as a Staff Scientist in 1988 and had increasing responsibility there, including key roles in the development of its research strategy and pipeline as its Head of Discovery Research. Dr. Williams served as the Chairman of the Board of Amnis Corporation. Dr. Williams served as a Director at Regulus Therapeutics Inc. since November 5, 2012 until June 01, 2017. He serves as a Member of the Strategic Advisory Board at Symphony Capital LLC. He had been a Member of Therapeutic Advisory Board of aTyr Pharma Inc. since March 1, 2011. Dr. Williams served as a Trustee of Fred Hutchinson Cancer Research Center and at ArtsFund in Seattle. He served as a Director of Ironwood Pharmaceuticals, Inc. since June 04, 2014 until April 1, 2019. He has been a Director of Aerovance, Inc. since November 16, 2006. He served as a Non-Employee Director of Ovid Therapeutics Inc. since January 21, 2016 until June 2021. Dr. Williams served as a Director of Cascadian Therapeutics, Inc. (alternate name, Oncothyreon Inc.) from October 2009 to October 9, 2013. Dr. Williams served as a Director of Anadys Pharmaceuticals Inc. from August 25, 2004 to May 29, 2009. He served as a Director of Array Biopharma Inc. from April 29, 2004 to August 15, 2011. He served as a Director of Seattle Genetics, Inc., from May 2001 to March 2005. He served as Member of Scientific Advisory Board at Mythic Therapeutics, Inc until 2025. Dr. Williams served as a Director of Genesis Research & Development Corporation Limited, Auckland, New Zealand, from 1995 to March 25, 2005 and Immunex Corporation since April 1996. He served as a Director of ZymoGenetics, Inc. from January 9, 2009 to November 2010. He served as a Member of Scientific Advisory Board at Implicit Bioscience Limited. Before entering the biotechnology industry, Dr. Williams served on the faculty of the Indiana University School of Medicine and the Department of Laboratory Medicine at the Roswell Park Memorial Institute in Buffalo, New York. Dr. Williams has served as the Chief Scientific Officer of Kamino Therapeutics, Inc., a biotechnology company, since February 2026. He has served on the board of Ironwood Pharmaceuticals, Incorporated from June 2014 to March 2019. Dr. Williams is the Author of over 100 articles focused on hematology, cytokine biology and immunology. Dr. Williams has B.S. in Biological Sciences from University of Massachusetts Lowell, Ph.D. in Physiology from State University of New York at Buffalo Roswell Park Memorial Institute Division in 1984, A.D. in Liberal Studies & Liberal Arts from Greenfield Community College in 1978.
Positions
- Company NameClimb Bio, Inc.Stock CodeCLYMPositionIndependent Chairman of the BoardColleagues
- AMAoife M. BrennanCEO, President & Director
- DEDouglas Edward WilliamsIndependent Chairman of the Board
- SASusan AltschullerCFO & Principal Accounting Officer
- PWPerrin WilsonChief Business Officer
- AVAdam VillaSenior Vice President of Technical Operations
- CAChandra AdamsSenior VP, General Counsel & Secretary
- AGAlexander G. CumboIndependent Director
- KCKimberlee Cobleigh DrapkinIndependent Director
- JAJudith A. DunnIndependent Director
- Company NameCamp4 Therapeutics CorporationStock CodeCAMPPositionIndependent Chairman
